Clinical updates, including trial initiations, enrollment status and data readouts and publications: Atheart Medical, Curebase, Exagen, Inbios, Intuitap Medical, Medical Microinstruments, Pear Therapeutics, Spinex, Vessi Medical.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Airstrip, Avita Biomedical, Biointellisense, Exactech, International Isotopes, Invivo Therapeutics, Radqual, RTI Surgical, Seegene, Symphonyai.
ISA Pharmaceuticals BV has closed a €26 million (US$30.76 million) funding round to advance its cancer immunotherapy product, ISA-101b, in the clinic, as the company aims to tackle the low response rates that hold back this therapeutic approach.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Carrot, Quidel, Ortho Clinical Diagnostics, Uvision360.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aditxt, Bardy Diagnostics, Dariohealth, Hillrom, Histosonics, Tada Medical.
In infectious disease research, most of the research into genetic determinants of susceptibility to infection and disease severity are focused on the host. For COVID-19, for example, the delta variant’s infectivity, and how likely infection is to lead to severe disease, is the focus of an intense research agenda. But host genetics, too, contribute to the consequences of infections. An ongoing study into the host genetics of SARS-CoV-2 infection has identified 13 such factors that affected either the likelihood of contracting SARS-CoV-2, or the severity of disease, gleaned from the data of 50,000 infected persons and 2 million controls.
New research suggests that ultraviolet (UV) light that operates at lower bandwidth than what currently exists in the market could be just as useful in inactivating the SARS-CoV-2 virus with less harmful effects on skin cells. Joint research by Asahi Kasei Corp. and Nara Medical University confirmed that 226 nanometer ultraviolet-C (UVC) LEDs can inactivate the SARS-CoV-2 virus that causes COVID-19 while having less effect on animal skin cells compared to 270 nm UVC LEDs.
LONDON – Final results of the community pilot in Liverpool, U.K., that used the controversial Innova Medical Group Inc. lateral flow device to test all comers for COVID-19, show new cases fell by 21% compared to other areas of the U.K., because infections were detected early and people quarantined sooner.
